ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconFacebook IconIcon FacebookGoogle Plus IconLayer 1InstagramCreated with Sketch.Linkedin IconIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerIcon Opinion QuotePositive ArrowIcon PrintRSS IconIcon SearchSite TitleTitle ChevronTwitter IconIcon TwitterYoutube Icon
Health Technology

Dr. Reddy's Laboratories Ltd.

  • 2,129.15 INR
  • -27.10
  • -1.26%
  • India
    Apr 24, 2018
  • Ticker
  • Prev. close
  • Market cap (INR)
  • Market cap (USD)
  • Shares

Business Summary

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others. The Global Generics segment is consist of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The PSAI segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with established pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates from hit generation to pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Financial Highlights

Mar 2017 INRUSD
Gross Profit73,531M1,096.54M
Operating income12,878M192.04M
Income before tax14,304M213.31M
Net income12,039M179.53M
Diluted EPS72.091.07
Dividends Per Share200.29
Total Assets219,821M3,385.24M
Total liabilities95,777M1,474.96M
Total equity124,044M1,910.27M
Operating cash flow21,216M316.38M
Currency in INRCurrency in USD

Historical Data

 Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017
Revenue 116,266M 132,170M 148,189M 154,708M 140,809M
Gross Profit 58,013M 72,466M 81,457M 87,272M 73,531M
Operating income 19,489M 24,119M 25,878M 28,806M 12,878M
Income before tax 21,572M 26,432M 27,968M 26,911M 14,304M
Net income 16,777M 21,515M 22,179M 20,013M 12,039M
EBITDA 25,038M 31,225M 33,978M 39,056M 24,155M
Diluted EPS 98.44 126.04 129.75 116.99 72.09
Dividends Per Share 15 18 20 20 20
Total Assets 142,369M 170,223M 194,762M 207,650M 219,821M
Total liabilities 69,564M 79,422M 83,460M 79,314M 95,777M
Total equity 72,785M 90,801M 111,302M 128,336M 124,044M
Operating cash flow 12,904M 19,280M 24,760M 41,613M 21,216M
 Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017
Revenue 2,136.24M 2,187.00M 2,423.62M 2,363.00M 2,099.83M
Gross Profit 1,065.91M 1,199.08M 1,332.22M 1,332.99M 1,096.54M
Operating income 358.08M 399.09M 423.23M 439.98M 192.04M
Income before tax 396.35M 437.36M 457.41M 411.03M 213.31M
Net income 308.25M 356.00M 362.73M 305.67M 179.53M
EBITDA 460.04M 516.67M 555.70M 596.54M 360.21M
Diluted EPS 1.80 2.08 2.12 1.78 1.07
Dividends Per Share 0.27 0.29 0.32 0.30 0.29
Total Assets 2,619.48M 2,850.23M 3,112.14M 3,135.64M 3,385.24M
Total liabilities 1,279.92M 1,329.85M 1,333.62M 1,197.68M 1,474.96M
Total equity 1,339.19M 1,520.38M 1,778.51M 1,937.95M 1,910.27M
Operating cash flow 237.09M 319.02M 404.94M 635.59M 316.38M

Valuation Measures

Mar 2017
Operating margin9.14%
Profit margin8.54%

Key executives

  • Co-Chairman, Chief Executive Officer & MD: Gunupati Venkateswara Prasad
  • President, CFO & Global Head-IT: Saumen Chakraborty
  • Chief Operating Officer: Erez Israeli
  • Secretary & Compliance Officer: Sandeep Poddar
  • EVP, Head-Emerging Markets & Global Generics: M. V. Ramana


  • Dr. Reddy's Holdings Ltd. (24.7%)
  • First State Investment Management (UK) Ltd. (6.2%)
  • OppenheimerFunds, Inc. (3.8%)
  • Life Insurance Corp. of India (3.5%)
  • Reliance Nippon Life Asset Management Ltd. (Invt Mgmt) (2.3%)
  • BlackRock Fund Advisors (2.1%)
  • Franklin Advisers, Inc. (1.9%)
  • Franklin Templeton Asset Management (India) Pvt Ltd. (1.8%)
  • Aditya Birla Sun Life AMC Ltd. (1.6%)

Contact Details

  • Website:
  • Address: Door No. 8-2-337, Road No. 3, Hyderabad, 500034, India
  • Phone: +91.40.49002900

Related Companies

  • Dr. Reddy's New Zealand Ltd.
  • Imperial Credit Pvt Ltd.
  • Ducere Pharma LLC/Otc Bus/
  • UCB SA /Established Product Bus/
  • Dr. Reddy's Laboratories SA
  • Dr. Reddy's Laboratories Ltd. (Russia)
  • Zenovus Biotech Pvt Ltd.
  • Reddy Holding GmbH
  • Dr. Reddy's Pharma SEZ Ltd.
  • Dr. Reddy's Bio-Sciences Ltd.
  • Promius Pharma LLC
  • Industrias Quimicas Falcon de Mexico SA de CV
  • DR Reddy's Laboratories (UK) Ltd.
  • Kunshan Rotam Reddy Pharmaceutical Co. Ltd.
  • Perlecan Pharma Pvt Ltd.
  • Macred India Pvt Ltd.
  • BASF SE /Pharmaceutical Contract Manufacturing Unit/
  • Reddy Pharma Italia SpA
  • Dowpharma /Small Molecules Business/
  • Dr. Reddy's Laboratories, Inc.
  • Laboratorios Litaphar SA
  • F. Hoffmann-La Roche Ltd. /Drug Ingredient Making Plant/
  • Trigenesis Therapeutics, Inc.
  • betapharm Arzneimittel GmbH
  • OctoPlus N.V.
  • Dr. Reddy's Laboratories (EU) Ltd
  • Cheminor Drugs


  • Novartis AG
  • Perrigo Co. Plc
  • Lupin Limited
  • Mylan N.V.
  • Pfizer Inc.
  • KRKA dd
  • Sanofi
  • Pfizer India Ltd.
  • Cipla Limited
  • Teva Pharmaceutical Industries Limited
  • GlaxoSmithKline Pharmaceuticals Limited
  • Sanofi India Limited
  • Takeda Pharmaceutical Co. Ltd.
  • Bayer AG
  • Endo International Plc
  • Chemical Works of Gedeon Richter Plc
  • Alkem Laboratories Ltd.
  • STADA Arzneimittel AG
  • Cadila Healthcare Limited
  • Sun Pharmaceutical Industries Limited
  • Abbott India Limited
  • Piramal Enterprises Ltd.
  • GlaxoSmithkline Consumer Healthcare Ltd
  • Fresenius SE & Co. KGaA
  • Thermo Fisher Scientific Inc.
  • Divi's Laboratories Limited
  • Aurobindo Pharma Ltd
  • Catalent Inc
  • Dishman Carbogen Amcis Ltd.
  • Cambrex Corporation
Last Updated on 24 Apr, 2018

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

3 months for $9

Get unlimited access
NAR site on phone, device, tablet

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media